APEX KSI-101 in DME – KSI-101 was well-tolerated KSI-101 2.5 mg (n=4) KSI-101 5 mg (n=4) KSI-101 10 mg (n=4) All KSI-101 (N=12) Summary of AEs in the Study eye, n (%) Subjects with ≥1 AEs 1 (25) 0 0 1 (8.3) Treatment-related AEs 0 0 0 0 Serious AEs 0 0 0 0 Treatment-related serious AEs 0 0 0 0 Severe AEs 0 0 0 0 AEs leading to study discontinuation 0 0 0 0 AEs in the Study Eye, n (%) Intraocular inflammation 0 0 0 0 Occlusive retinal vasculitis 0 0 0 0 Cataract 0 0 0 0 Cataract traumatic* 1 (25.0) 0 0 1 (8.3) Elevated IOP 0 0 0 0 Eye Pain 0 0 0 0 AE, Adverse event; IOP, intraocular pressure. Events are investigator reported. Adverse events are treatment-emergent events with start date ≥first study drug date and ≤last study drug date + 28 days. * Anterior traumatic cataract due to aqueous humor routine sample 70